The bioreactor hums, a stainless-steel vessel where biology becomes medicine. For decades, the only way to know what was happening inside was to pull a sample, walk it to a lab, and wait hours for an offline assay. The process was a necessary pause, a blind spot in the making of a biologic drug. The team at IRUBIS, a Munich-based startup founded in 2017, decided the pause was the problem. Their answer is a device called Monipa, a mid-infrared (MIR) spectrometer that fits directly into the process line, offering a real-time read on proteins, metabolites, and contaminants as they flow by [irubis.com]. It is a sensor designed not for the lab bench, but for the factory floor, a quiet bet that the most valuable data in biomanufacturing is the data you don't have to wait for.
The Wedge of Real-Time
IRUBIS's core proposition is deceptively simple: replace the offline sample with an inline measurement. In biopharmaceutical manufacturing, particularly for complex molecules like monoclonal antibodies or mRNA, maintaining precise conditions is everything. A shift in pH, a dip in nutrient concentration, or the appearance of an unwanted byproduct can derail a batch worth millions. The industry standard, Process Analytical Technology (PAT), has long promised real-time monitoring, but adoption has been hampered by complexity and cost. IRUBIS attacks this gap with a hardware-software bundle. The Monipa system uses a single-use sensor interface that slots directly into bioreactor or filtration lines, taking continuous MIR readings. The accompanying software uses machine learning models to interpret the spectral data, translating light absorption patterns into concentrations of target molecules like proteins, excipients, and even nucleic acids [Perplexity Sonar Pro Brief]. The company's pitch is one of simplification, turning a technique historically confined to analytical chemists into a tool a process engineer can use.
The product's design choices reveal its intended user. The single-use interface eliminates cross-contamination and tedious cleaning validation, a nod to the strict hygiene protocols of Good Manufacturing Practice (GMP) environments. The company reports the technology is advancing its GMP readiness, a critical step for adoption in commercial production [17, 2026]. Furthermore, IRUBIS has demonstrated integrations with established bioprocessing hardware, like the Repligen KrosFlo KR2i tangential flow filtration system, showing it can plug into existing workflows rather than demanding a full overhaul [9, 2026]. This is a wedge strategy: start by solving a specific, painful bottleneck in process development and small-scale production, then expand into broader control applications.
The Team and the Traction
IRUBIS was founded by a trio with deep roots in the technical challenge they are solving: Anja Müller, Alexander Geißler, and Lorenz Sykora-Mirle, who serves as CEO [Perplexity Sonar Pro Brief]. The backgrounds point to a blend of scientific and entrepreneurial focus, with Sykora-Mirle's profile indicating a foundation in physics and spectroscopy [LinkedIn]. They have navigated the early-stage funding landscape typical of European deep tech, securing backing from a mix of specialist and public sources.
The company's investor list includes BioProcess360, a venture firm focused on bioprocessing technologies, alongside German public-funding stalwarts High-Tech Gründerfonds and the European Innovation Council (EIC) Fund [PitchBook, Unknown], [High-Tech Gründerfonds, Dec 2020], [European Innovation Council (EIC) Fund, 2023]. Total disclosed funding is approximately $3.4 million, anchored by a €2.8 million seed round [PitchBook, Unknown], [16, 2026]. This capital has funded the development and initial commercial push of the Monipa system.
Traction is often the hardest metric to pin down for hardware startups selling into conservative industries. IRUBIS does not publicly name customers, but claims its technology is "already in use by key opinion leaders in the biopharma industry" [19, 2026]. In the jargon of life sciences, a 'key opinion leader' is more than a reference account; it is an endorsement from an institution whose adoption signals technical credibility to the broader market. The company is also actively hiring for roles like Data Analyst | Spectroscopy and Front-End Developer, suggesting a scaling of both its scientific analysis capabilities and its software interface [irubis.com, Unknown], [3, 2026].
| Founder | Role |
|---|---|
| Lorenz Sykora-Mirle | Co-Founder & CEO |
| Anja Müller | Co-Founder |
| Alexander Geißler | Co-Founder |
| Source: Company materials and investor profiles [Perplexity Sonar Pro Brief], [LinkedIn] |
The Competitive Field
IRUBIS does not operate in a vacuum. The market for bioprocess monitoring is crowded with established players and specialized startups, each approaching the problem of real-time data from a different angle.
- The Incumbent Giants. Companies like Repligen and 908 Devices represent the competitive landscape IRUBIS must navigate. Repligen is a multi-billion dollar provider of bioprocessing technologies, offering a wide array of filtration, chromatography, and analytics systems. Competing here means offering a best-in-class sensor that can integrate into Repligen's own ecosystem, which IRUBIS has begun to do [9, 2026]. 908 Devices focuses on handheld and desktop mass spectrometry for bioprocess analysis, a different but adjacent technology. The incumbents' advantage is distribution and trust; their weakness can be slower innovation cycles.
- The Spectroscopy Niche. Other startups are also leveraging advanced spectroscopic techniques,Raman, NIR, MIR,for bioprocess monitoring. IRUBIS's differentiation rests on its specific focus on mid-infrared spectroscopy for a broad set of molecules in aqueous solutions, combined with its single-use, inline form factor and machine-learning-driven software. The bet is that this combination offers a better balance of specificity, ease of use, and cost for certain critical measurements.
The company's path is not to displace the giants overnight, but to carve out a defensible niche where its technology offers a clear, measurable advantage in speed and simplicity, then expand from that beachhead.
The Risks in the Recipe
For all its technical promise, IRUBIS faces hurdles inherent to its category. The sales cycles in biopharma are long, often stretching 18 to 24 months for capital equipment. Convincing risk-averse manufacturers to change a validated process,even for a clear benefit,requires extensive testing and regulatory comfort. The company's progress toward GMP readiness is a direct response to this, but it is a milestone, not a finish line [17, 2026].
Financing is another watchpoint. The approximately $3.4 million in total disclosed funding is substantial for early R&D but modest for scaling hardware manufacturing and a global commercial footprint in the capital-intensive biotech sector [PitchBook, Unknown]. The company's next logical step would be a larger venture round to fund that expansion, but the current market for hardware deep tech is selective. Success will depend on converting those early "key opinion leader" engagements into repeatable, referenceable sales that de-risk the story for Series A investors.
Finally, the technology itself, while powerful, has limits. MIR spectroscopy is excellent for many organic molecules, but it may not be a universal sensor for every possible contaminant or byproduct in a complex broth. IRUBIS's expansion into applications like ultra-/diafiltration suggests it is systematically broadening its addressable market within the downstream processing suite, a necessary strategy to build a sizable business [17, 2026].
The Next Twelve Months
The coming year will likely determine whether IRUBIS transitions from a promising tool used by pioneers to a standard piece of kit in development labs. Key milestones to watch include the formal announcement of a GMP-ready product, the disclosure of a marquee customer name (beyond the anonymized opinion leaders), and a subsequent funding round to fuel commercial scaling. The company's ability to move beyond process development and into at-scale commercial manufacturing will be the ultimate test of its value proposition.
There is a cultural shift embedded in a device like Monipa. It asks a question of an industry built on batch records and offline quality control: what if you didn't have to wait? What if the quality check was the process itself, a continuous stream of data instead of a periodic audit? For IRUBIS, the bet is that the future of making biologic medicines looks less like a chemistry lab, with its discrete samples and delayed results, and more like a modern data center, where every critical variable is monitored in real time. The sensor in the line is the first step toward that vision, a small window into the broth that aims to make the entire process less of a black box.
Sources
- [irubis.com] IRUBIS Company Website | https://irubis.com/
- [Perplexity Sonar Pro Brief] IRUBIS Company Brief | [Web-grounded summary]
- [High-Tech Gründerfonds, Dec 2020] IRUBIS Portfolio Page | https://www.htgf.de/en/portfolio/htgffamily/irubis/
- [European Innovation Council (EIC) Fund, 2023] IRUBIS GmbH EIC Fund Portfolio | https://eic.eic.europa.eu/investments/eic-fund-portfolio/irubis-gmbh_102023
- [PitchBook] IRUBIS Funding Overview | [Aggregate data]
- [LinkedIn] Lorenz Sykora-Mirle Profile | https://www.linkedin.com/company/irubis/
- [17, 2026] Analytica-World Article on IRUBIS pre-Series A | https://www.analytica-world.com/en/news/1184321/start-up-aims-to-accelerate-bioprocess-development.html
- [9, 2026] IRUBIS Integration with Repligen System | https://irubis.com/monipa/
- [19, 2026] IRUBIS Claim on Key Opinion Leader Use | [Company claim]
- [3, 2026] IRUBIS Job Posting for Front-End Developer | [Company job page]